[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349708-105":59,"doc-detail-349708-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mirvetuximab-soravtansine-mechanism-of-action-clinical-and-translational-science","Mirvetuximab Soravtansine - Mechanism of Action, Clinical and Translational Science","","Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor alpha (FRα) using a cleavable sulfo-SPDB linker. After MIRV-FRα binding, internalization and degradation release DM4 (and S-methyl-DM4), which suppress microtubule dynamics, driving cell cycle arrest and apoptosis, with a potential bystander effect. The therapy addresses platinum-resistant epithelial ovarian cancers where outcomes remain poor despite initial platinum responses. The MIRASOL Phase 3 trial showed improved response, progression-free survival, and overall survival in high FRα-expression disease versus chemotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mirvetuximab-soravtansine-mechanism-of-action-clinical-and-translational-science/349708/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mirvetuximab-soravtansine-mechanism-of-action-clinical-and-translational-science/349708.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the mechanism of action of mirvetuximab soravtansine (MIRV)?","Question",{"text":112,"@type":113},"MIRV binds FRα and is internalized, after which DM4 is released intracellularly (and forms S-methyl-DM4). Both suppress microtubule dynamics, causing cell cycle arrest and apoptosis, with possible bystander effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is MIRV considered attractive for epithelial ovarian cancers?",{"text":117,"@type":113},"FRα-overexpression is present in at least 90% of relevant epithelial ovarian tumor cells, and FRα enables internalization of the antibody-drug conjugate, supporting targeted delivery of the cytotoxic payload.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the MIRASOL Phase 3 trial show for patients with high FRα-expression platinum-resistant disease?",{"text":121,"@type":113},"Compared with chemotherapy, MIRV demonstrated higher objective response rate, improved progression-free survival, and improved overall survival in high FRα-expression PROC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349708,1790190623,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Clinical and Translational Science   \n MINI REVIEW  OPEN ACCESS   \nMirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science  \nRajeev Menon1  | Emarjola Bako2  | Shuhan Liu1  | James Stec3  | Sheetal Thakur4  | Emily Deutschman5  | Olga Ab5  | Shweta Jain6   \n1Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA | 2Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, Illinois,  \nUSA | 3Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA | 4Regulatory Affairs Oncology, AbbVie Inc., North Chicago, Illinois, USA | 5Precision  \nMedicine Oncology, AbbVie Inc., Waltham, Massachusetts, USA | 6Clinical Development Oncology, AbbVie Inc., North Chicago, Illinois, USA Correspondence: Rajeev Menon ([rajeev.menon@abbvie.com](rajeev.menon@abbvie.com); [clinpharm.publications@abbvie.com](clinpharm.publications@abbvie.com))  \nReceived: 3 September 2025 | Revised: 3 November 2025 | Accepted: 21 November 2025  \nKeywords: antibody-drug conjugate | mechanism of action | mirvetuximab soravtansine | ovarian cancer  \nABSTRACT  \nMirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)-targeting antibody via the cleavable sulfo-SPDB linker. MIRV targets and binds to FRα with high affinity and specificity, releasing the DM4 payload intracellularly following MIRV-FRα complex internalization and degradation. DM4 and its metabolite S-methyl-DM4 suppress microtubule dynamic instability, which triggers cell cycle arrest and apoptosis. Selective FRα-overexpression in ≥90% of epithelial ovarian tumor cells and its ability to internalize large molecules make it a highly attractive ADC target for epithelial ovarian cancers (including primary peritoneal and fallopian tube cancers) . Although up to 80% of patients initially respond to platinum-based therapies, the majority of tumors will recur and become platinum-resistant. Unfortunately, platinum-resistant ovarian cancer (PROC) carries a poor prognosis with an overall survival of 12–14 months from the time of platinum-resistance, and prior to MIRV approval in 2022, little had changed in treatment options for decades. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomaldoxorubicin, or topotecan) in patients with high (≥ 75%) FRα-expression PROC, showing an objective response rate of 42% versus 16%, a median progression-free survival of 5.6 versus 4.0 months, and an overall survival of 16.5 versus 12.8 months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.  \n1 | Introduction  \nEpithelial ovarian cancer (including primary peritoneal and fallopian tube cancer) is among the deadliest gynecological malignancies. In 2021, an estimated 238,000 women were living with ovarian cancer in the US, but the 5-year survival rate was only 50.9% between 2014 and 2020 [1] . Epithelial ovarian cancers can be divided into several histologic subtypes. High grade-serous ovarian cancer (HGSOC) is most common, accounting for 70%– 75% of all ovarian cancers [2, 3] . Other less common subtypes include low grade-serous ovarian cancer, endometrioid carcinomas, clear-cell carcinomas, and mucinous carcinomas [2] .  \nLittle has changed over the past decades in ovarian cancer treatment, with standard management including cytoreductive surgery and platinum-based chemotherapy. Platinum agents cause DNA damage in tumors, the majority of which have impaired DNA repair mechanisms [4] . As a result, accumulating DNA double-strand breaks in tumor cells impair replication and lead to apoptosis. Although up to 80% of patients initially respond to platinum-based therapies [5, 6], the majority will develop recurrent disease. Unfortunately, most recurrent tumors are or become platinum-resistant, currently defined as disease progression ≤6months after platinum-based therap","cbCaiutk3bRG5rif","https://ap.wps.com/l/cbCaiutk3bRG5rif","pdf",1552035,"English","# Abstract\n# Introduction\n## Epithelial ovarian cancer burden and subtypes\n## Platinum resistance and unmet need\n# Mechanism of Action\n## FRα targeting, internalization, payload release\n## Microtubule suppression and cell death\n# Indication\n# Dosage and Administration\n## IV dosing schedule","[{\"question\":\"What is the mechanism of action of mirvetuximab soravtansine (MIRV)?\",\"answer\":\"MIRV binds FRα and is internalized, after which DM4 is released intracellularly (and forms S-methyl-DM4). Both suppress microtubule dynamics, causing cell cycle arrest and apoptosis, with possible bystander effects.\"},{\"question\":\"Why is MIRV considered attractive for epithelial ovarian cancers?\",\"answer\":\"FRα-overexpression is present in at least 90% of relevant epithelial ovarian tumor cells, and FRα enables internalization of the antibody-drug conjugate, supporting targeted delivery of the cytotoxic payload.\"},{\"question\":\"What did the MIRASOL Phase 3 trial show for patients with high FRα-expression platinum-resistant disease?\",\"answer\":\"Compared with chemotherapy, MIRV demonstrated higher objective response rate, improved progression-free survival, and improved overall survival in high FRα-expression PROC.\"}]","Mirvetuximab Soravtansine - Mechanism of Action, Clinical and Translational Science | PDF",1790085144,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/632f84a0993012fb72ffffdcfe48a320.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f5f245d23d2de7e7b7e1419a58dc404.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ec93fae507c309bed7530020d78350f.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3383f6679b695ae1b4257422886d0968.webp",980,1287]